U.S. court voids $448 million award against AbbVie, AndroGel partner
(Reuters)-In antitrust cases accusing AbbVie of illegal attempting to hold generic copies of its Testosterone replenishment medication androgel off the market on Wednesday, the federal appeals court issued an order which ordered AbbVie Inc and its affiliate to disperse the benefit of €448 million.
The Federal Trade Commission's decision in a situation of third US
Circuit Court of Appeals in Philadelphia reported that there was a violation of jurisdiction under federal law of the lower court judge who directed the merger of AbbVie and Besins Healthcare Inc.
The court of appeal further reaffirmed that AbbVie and Besins were found to be accountable for the monopolization under the basis of submitting a flagrant patent infringement litigation against Perrigo Co to postpone the release of generic AndroGel.
It also reintroduced further FTC arguments and referred the matter for further litigation to the lower court.
AbbVie and Besins representatives did not return calls for comments instantly.
The FTC did not answer related questions instantly.
(Jonathan Stempel 's article in New York; Bernadette Baum 's report)